Speculators Bet on Arena Pharma (ARNA) Getting Over $10 Following PDUFA
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) volatility is up 7 percent from Monday's close to 238 percent or so, heading into the pharma's PDUFA date for its weight-loss drug lorcaserin. Volatility is up 208 percent from its trailing annual average.
Shares have been wild lately into the numbers, with a rogue SA article last Friday causing investors to question potential for the drug.
Positioning is taking shape well, with July 10 call contracts seeing the most volume of any option being traded currently, at just under 11,000 contracts. Those option prices are 1.5 percent lower Tuesday. Volume on June 10 calls is also high at 6,200 contracts.
Shares of Arena are down 2.6 percent.
Shares have been wild lately into the numbers, with a rogue SA article last Friday causing investors to question potential for the drug.
Positioning is taking shape well, with July 10 call contracts seeing the most volume of any option being traded currently, at just under 11,000 contracts. Those option prices are 1.5 percent lower Tuesday. Volume on June 10 calls is also high at 6,200 contracts.
Shares of Arena are down 2.6 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
- Ross Stores (ROST) 9K contracts of September 220 puts trade into quarter results
- Increasing unusual call volume: IWF UROY ROST TECK CRK BNTX BITI MTDR BRUN TECH ETH BJ MUX CPRT
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
